Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin
- 1 October 1998
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 82 (8) , 12P-18P
- https://doi.org/10.1016/s0002-9149(98)00660-2
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- On the Mechanism of the Antifibrinolytic Activity of Plasma Carboxypeptidase BJournal of Biological Chemistry, 1997
- Coronary Plaque DisruptionCirculation, 1995
- Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis InhibitorJournal of Biological Chemistry, 1995
- Plasmin-Mediated Activation of Contact System in Response to Pharmacological ThrombolysisCirculation, 1995
- Molecular and Cellular Biology of Blood CoagulationNew England Journal of Medicine, 1992
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.Journal of Clinical Investigation, 1990
- Activation/inactivation of human factor V by plasminBlood, 1989
- Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA)Thrombosis Research, 1988